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Introduction: The efﬁcacy of auditing is still a subject of debate and concerns exist whether auditing
promotes risk averse behaviour of physicians. This study evaluates the achievements made in colorectal
cancer surgery since the start of a national clinical audit and assesses potential signs of risk averse
behaviour.
Methods: Data were extracted from the Dutch ColoRectal Audit (2009e2016). Trends in outcomes were
evaluated by uni and multivariable analyses. Patients were stratiﬁed according to operative risks and
changes in outcomes were expressed as absolute (ARR) and relative risk reduction (RRR). To assess signs
of risk averse behaviour, trends in stoma construction in rectal cancer were analysed.
Results: Postoperative mortality decreased from 3.4% to 1.8% in colon cancer and from 2.3% to 1% in rectal
cancer. Surgical and non-surgical complications increased, but with less reintervention. For colon cancer,
the high-risk elderly patients had the largest ARR for complicated postoperative course (6.4%) and
mortality (5.9%). The proportion of patients receiving a diverting stoma or end colostomy after a (L)AR
decreased 11% and 7%, respectively. In low rectal cancer, patients increasingly received a non-diverted
primary anastomosis (5.4% in 2011 and 14.4% in 2016).
Conclusions: No signs of risk averse behaviour was found since the start of the audit. Especially the high-
risk elderly patients seem to have beneﬁtted from improvements made in colon cancer treatment in the
past 8 years. For rectal cancer, trends towards the construction of more primary anastomoses are seen.
Future quality improvement measures should focus on reducing surgical and non-surgical complications.
© 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical
Oncology. All rights reserved.
Introduction
Clinical auditing is increasingly considered as an important tool
for quality assessment and improvement [1e6]. In an audit, base-
line risk adjusted and benchmarked feedback information on per-
formance is provided to professionals, thereby facilitating
improvement cycles [7e9]. Additionally, auditing can also be used
to evaluate guideline implementation and to monitor new treat-
ments. This is illustrated by one of the ﬁrst audits in rectal cancer
that evaluated the implementation of Total Mesorectal Excision for
rectal cancer [10].
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However, the effectiveness of audits is still a subject of debate. A
Cochrane review published in 2012 reported a positive but small
effect of auditing on healthcare outcomes [11]. However, the
magnitude of improvements varied strongly between studies.
Although auditing can lead to overall improvements in outcomes
over time, a still largely unresolved question is whether clinically
relevant subgroups equally beneﬁt from the advances made in
colorectal cancer (CRC) treatment. Furthermore, critics have argued
that improvements might also be related to patient selection by
excluding high risk patients from surgery as a result of auditing, a
phenomenon called risk aversion. Another example of risk averse
behaviour could be avoiding the risks related to anastomotic
leakage by performing more end-colostomies instead of low
anastomoses.
Therefore, the purpose of this population-based analysis was to
study outcomes of CRC treatment for different risk-stratiﬁed sub-
groups of patients since the start of the Dutch ColoRectal Audit
(DCRA). In addition, potential risk averse behaviour was evaluated
by determining proportions of surgically treated CRC patients over
time based on the Netherlands Cancer Registry (NCR) and by ana-
lysing time trends of the proportion constructed colostomies in
surgically treated (low) rectal cancer patients.
Materials and methods
Data were extracted from the DCRA, formerly known as the
Dutch Surgical Colorectal Audit (DSCA). This audit collects infor-
mation on patient, tumour, treatment and short-term outcome
characteristics of all patients undergoing a resection for primary
CRC in the Netherlands [12]. Every year, each hospital makes
several structure, process and outcomes measures transparent on a
hospital level to health care payers.
To enable a comprehensive view of CRC treatment over time and
possible patient selection as a sign of risk averse behaviour, another
independent source of data on both surgically and non-surgically
treated CRC patients in the Netherlands was consulted: the NCR.
The NCR uses the digital pathology archive (PALGA) and the Na-
tional Registry of Hospital Discharge Diagnoses to notify of a newly
diagnosed CRC [13].
Patients
For this study, no ethical approval or informed consent was
required under Dutch law. All patients (n ¼ 78,866) undergoing a
surgical resection and registered in the DCRA between January 1st,
2009 and December 31st, 2016, were evaluated. Minimal data re-
quirements were information on tumour location, date of surgery
and 30-day/in-hospital mortality (n ¼ 78,416). For the purpose of
this study, it was decided to include only planned (elective) surgical
resections and excluding multiple synchronous colorectal tumours
[14]. Patients diagnosed through the CRC screening programme,
which started in 2014, were also excluded. The screening popula-
tion was considered a different (more favourable) CRC population
that might inﬂuence on the studied outcomes over time, making
interpretation of auditing effects more difﬁcult [15,16]. This resul-
ted in a total eligible number of 59,857 patients.
Data extraction and outcome parameters
The following data were extracted from the DCRA: patient and
disease characteristics, procedural characteristics and post-
operative outcome within 30 days after resection or in-hospital
events. To evaluate overall trends in treatment for CRC, data on
type of treatment for all registered CRC patients were extracted
from the NCR. Type of treatment in the NCR was categorized as;
resection - elective, resection - non-elective, local excision, poly-
pectomy, (chemo)radiotherapy (no resection), systemic therapy,
radiotherapy and systemic therapy, only metastasectomy and/or
radiotherapy for metastasis, no treatment, resection for other
indication (incidental ﬁnding), treatment unknown.
Outcome parameters consisted of complicated postoperative
course (post-operative complication resulting in a hospital stay>14
days and/or reintervention and/or postoperative mortality), in-
hospital or 30-day mortality, surgical complication, non-surgical
complication, reintervention (surgical, endoscopic or radiologic),
postoperative length of stay (LOS), and readmission.
Data analysis
Analyses were performed separately for colon and rectal can-
cer. The ﬁrst two years (2009e2010) were excluded from trend
analyses, because different variables of interest, such as type of
complication or reinterventions, were not yet registered and
because of not-registered eligible patients in the DCRA of >5%
compared with the NCR [12]. For 2009e2010, patient and tumour
characteristics were only provided for informative purposes. To
evaluate changes over time, data from the years 2011e2012 were
compared to 2015e2016 and tested for statistical signiﬁcance
with a non-parametric Mann Whitney U test for non-normally
distributed continuous variables (e.g. LOS, with a Bonferroni
correction for multiple testing) or chi2-test for categorical
variables.
To evaluate differences in outcomes, uni and multivariable lo-
gistic regression analysis was used. The following factors were
included in the multivariable analysis to adjust for differences in
risks; sex, age, American Society of Anesthesiologists (ASA) score,
Charlson comorbidity score, Body Mass Index (BMI), any pre-
operative abdominal surgery (not further speciﬁed in the DCRA),
tumour related complications, and pathological(p)T-stage. For co-
lon cancer, the location of the tumour within the colon was added
to the risk adjustment model, and for rectal cancer the tumour
distance from the anal verge, clinical(c)T-stage, pre-operative
radiotherapy (no radiotherapy, short course radiotherapy or che-
moradiotherapy) and surgical procedure (LAR, APR or other) were
added to the risk adjustment model. Further details on the risk
adjustment model as used in the DCRA are described in previous
studies [17].
Risk stratiﬁed analysis of raw data was done to be able to
determine the absolute (ARR) and relative risk reductions (RRR)
over the years for different subgroups. Ten subgroups of patients
were deﬁned based on relevance for surgical treatment (tumour
stages: non-locally advanced/non-metastatic (T1-3N0-2M0),
locally advanced/non-metastastic (T4N0-2M0) and metastatic
(T1-4N0-2M1)) and on known risk factors for postoperative out-
comes (ASA score (IeII vs. IIIeIV) and age (60, 61e70, 71e80,
81 years)).
A p-value of less than 0.05 was considered statistically signiﬁ-
cant. All analyses were performed in SPSS 24.0 Statistics for Win-
dows (Armonk, NY: IBM Corp).
Results
Baseline characteristics
A total of 40,004 colon cancer and 19,853 rectal cancer patients
were included for analysis. Table 1 shows the characteristics of
colon and rectal cancer patients per two years during the period
2009e2016. For colon and rectal cancer, patients in 2015e2016
compared to 2011e2012 had a higher ASA (IIIþ), Charlson comor-
bidity score (3þ) and BMI(30þ).
M.P.M. de Neree tot Babberich et al. / European Journal of Surgical Oncology 44 (2018) 1361e13701362
Table 1
Patient-, tumour- and treatment characteristics of patients with primary CRC undergoing a resection between 2009 and 2016.
Patient Colon Rectum
2015e2016 vs
2011e2012
2015e2016 vs
2011e2012
Year of operation 2009
e2010
2011
e2012
2013
e2014
2015
e2016
P-value 2009
e2010
2011
e2012
2013
e2014
2015
e2016
P-value
Total patients 8458 10,357 10,580 10,609 4029 5254 5324 5246
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Age 60 1479
(18)
1719
(17)
1759
(17)
1825
(17)
p ¼ 0.610 1057
(26)
1395
(27)
1304
(25)
1366
(26)
p ¼ 0.572
61e70 2349
(28)
2997
(29)
3140
(30)
3056
(29)
1343
(33)
1760
(34)
1855
(35)
1745
(33)
71e80 2894
(34)
3626
(35)
3715
(35)
3707
(35)
1185
(29)
1551
(30)
1566
(29)
1544
(29)
81 1734
(21)
2013
(19)
1963
(19)
2010
(19)
444
(11)
548
(10)
599
(11)
591
(11)
Gender Male 4403
(52)
5422
(52)
5611
(53)
5658
(53)
p ¼ 0.151 2471
(61)
3253
(62)
3380
(64)
3337
(64)
p ¼ 0.077
ASA score IeII 6301
(76)
7916
(77)
8045
(76)
7782
(73)
p < 0.001 3293
(84)
4383
(84)
4426
(83)
4300
(82)
p ¼ 0.031
IIIþ 1952
(24)
2419
(23)
2528
(24)
2826
(27)
651
(17)
868
(17)
898
(17)
952
(18)
Unknown/missing 205 22 7 1 86 5 1 1
Charlson Score 0 4551
(54)
5137
(50)
5009
(47)
4882
(46)
p < 0.001 2537
(63)
3047
(58)
2984
(56)
2903
(55)
p < 0.001
1 1865
(22)
2442
(24)
2483
(24)
2350
(22)
789
(20)
1114
(21)
1103
(21)
1035
(20)
2 1187
(14)
1567
(15)
1718
(16)
1732
(16)
446
(11)
652
(12)
770
(15)
781
(15)
3þ 833
(10)
1201
(12)
1364
(13)
1624
(15)
258 (6) 443 (8) 468 (9) 534
(10)
Unknown/missing 22 10 6 21 11 3 4 4
BMI (kg/m2) <18.5 111 (2) 149 (2) 168 (2) 171 (2) p < 0.001 56 (2) 83 (2) 93 (2) 83 (2) p < 0.001
18.5e25 2776
(43)
3978
(40)
4154
(40)
4100
(39)
1414
(43)
2046
(40)
2143
(41)
2041
(40)
26e30 2510
(39)
4098
(42)
4221
(41)
4077
(39)
1321
(40)
2136
(42)
2170
(42)
2107
(41)
>30 1116
(17)
1656
(17)
1793
(17)
2057
(20)
477
(15)
809
(16)
824
(16)
911
(18)
Unknown/missing 1945 476 244 204 762 182 95 111
Previous abdominal
surgery
Yes 2961
(36)
3696
(36)
3906
(37)
3783
(36)
P ¼ 0.916 1166
(29)
1615
(31)
1651
(31)
1587
(30)
p ¼ 0.527
Tumour
Location of Tumour Ascending colon up to and
including hepatic ﬂexure
3885
(46)
4767
(46)
4915
(47)
4905
(46)
p ¼ 0.014
Transverse colon up to and
including splenic ﬂexure
823
(10)
959 (9) 1048
(10)
1072
(10)
Descending colon 450 (5) 583 (6) 562 (5) 659 (6)
Sigmoid colon 3300
(39)
4048
(39)
4055
(38)
3973
(37)
Distance from anal verge 5 cm 1385
(37)
1891
(38)
2003
(39)
1926
(37)
p ¼ 0.029
6e10 cm 1551
(41)
2000
(40)
2009
(39)
2026
(39)
>10 cm 814
(22)
1049
(21)
1106
(22)
1210
(23)
280 316 207 91
Pre-operative tumour
complications
Yes 816
(10)
3152
(31)
3975
(38)
3106
(29)
p ¼ 0.027 287 (7) 1308
(25)
1404
(26)
934
(18)
p < 0.001
Clinical tumour T-stage cT1 147 (4) 207 (4) 240 (5) 282 (5) p < 0.001
cT2 875
(24)
1270
(25)
1154
(22)
1237
(24)
cT3 1947
(52)
2855
(56)
3236
(61)
2997
(57)
cT4 395
(11)
434 (9) 475 (9) 583
(11)
cTX/Unknown 353 (9) 333 (7) 206 (4) 153 (3)
missing 313 157 14 1
Pathological T stage (y)pT0-1 679 (8) 927 (9) 959 (9) 1169
(11)
p < 0.001 537
(14)
947
(18)
1056
(20)
1085
(21)
p ¼ 0.005
(y)pT2 1447
(17)
1841
(18)
1861
(18)
1873
(18)
1240
(32)
1645
(31)
1649
(31)
1543
(30)
(y)pT3
(continued on next page)
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An overview of 97,254 CRC patients diagnosed with primary CRC
in the Netherlands between 2009 and 2015 based on the NCR (2016
not yet available) is provided in Table 2. Total number of patients
and corresponding proportions for each speciﬁed type of treatment
are displayed for each year, with screening patients included since
2014. The number of elective resections increased, but with a
relative decrease of 4% compared to other types of treatment,
mainly related to the absolute and relative increase in endoscopic
Table 1 (continued )
Patient Colon Rectum
2015e2016 vs
2011e2012
2015e2016 vs
2011e2012
Year of operation 2009
e2010
2011
e2012
2013
e2014
2015
e2016
P-value 2009
e2010
2011
e2012
2013
e2014
2015
e2016
P-value
Total patients 8458 10,357 10,580 10,609 4029 5254 5324 5246
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
5081
(61)
6120
(59)
6190
(59)
5913
(56)
1911
(49)
2412
(46)
2379
(45)
2375
(45)
(y)pT4 1088
(13)
1398
(14)
1541
(15)
1627
(15)
237 (6) 224 (4) 223 (4) 219 (4)
Unknown/missing 163 71 29 27 105 28 18 31
Tumour stage (pathological
or clinical)*
stage 0 69 (1) 175 (2) 71 (1) 47 (0) p < 0.001
stage 1 1697
(20)
2097
(20)
2243
(21)
2389
(23)
726
(18)
978
(19)
950
(18)
1121
(21)
P < 0.001
stage 2 3159
(37)
3797
(37)
3846
(36)
3766
(35)
787
(20)
986
(19)
1008
(19)
975
(19)
stage 3 2495
(29)
3140
(30)
3281
(31)
3374
(32)
1299
(32)
2251
(43)
2700
(51)
2582
(49)
stage 4 892
(11)
1067
(10)
1105
(10)
1015
(10)
315 (8) 362 (7) 340 (6) 384 (7)
stage X 146 (2) 81 (1) 34 (0) 18 (0) 903
(22)
679
(13)
327 (6) 191 (4)
Work-up
Pre-operative visualisation
of entire colon
Yes 5816
(70)
7956
(77)
8666
(82)
8801
(83)
p < 0.001 3032
(78)
4424
(86)
4626
(88)
4521
(87)
P ¼ 0.182
Unknown/missing 192 69 31 23 159 92 39 31
Patient discussed in MDT Yes 4977
(63)
8528
(83)
9835
(94)
10,076
(95)
p < 0.001 3520
(91)
5104
(97)
5251
(99)
5188
(99)
p < 0.001
Unknown/missing 584 134 69 25 176 15 8 6
Neo adjuvant
chemotherapy (colon)
Yes 95 (1) 201 (2) 228 (2) 253 (2) p ¼ 0.027
Unknown/missing 294 439 409 512
Neo adjuvant radiotherapy
(rectum)
No 760
(20)
869
(17)
1461
(27)
1997
(38)
p < 0.001
SCRT-IS 1783
(44)
2087
(40)
1429
(27)
828
(16)
SCRT-DS 136 (3) 274 (5) 465 (9) 492 (9)
CRT/long course 1351
(34)
2026
(39)
1970
(37)
1936
(37)
Surgery
Procedure (colon) Ileocecal resection 106 (1) 122 (1) 89 (1) 59 (1) p < 0.001
Right hemicolectomy 3875
(48)
4778
(47)
5042
(49)
5144
(50)
Transverse colon resection 255 (3) 295 (3) 232 (2) 236 (2)
Left hemicolectomy 773
(10)
985
(10)
1107
(11)
1102
(11)
Sigmoid resection 3128
(38)
3911
(39)
3900
(38)
3838
(37)
Unknown/missing 321 266 210 230
Procedure (rectum) (Low) anterior resection 2426
(62)
3458
(66)
3496
(66)
3457
(66)
p < 0.001
Abdominoperineal resection 1285
(33)
1526
(29)
1515
(29)
1413
(27)
Not further speciﬁed 202 (5) 224 (4) 282 (5) 358 (7)
Unknown/missing 117 48 32 25
Surgical approach Open 4897
(58)
4929
(48)
3477
(33)
2185
(21)
p < 0.001 2578
(64)
2527
(48)
1514
(29)
1053
(20)
p < 0.001
Laparoscopic 3522
(42)
5418
(52)
7079
(67)
8390
(79)
1424
(36)
2724
(52)
3804
(72)
4187
(80)
Unknown/missing 39 10 24 34 28 5 7 13
Laparoscopic conversion No 68 (12) 4366
(86)
6001
(87)
7271
(89)
p < 0.001 46 (21) 2089
(86)
3076
(88)
3570
(92)
p < 0.001
Unknown/missing 2960 312 152 176 1201 294 314 307
MDT: Multidisciplinary Team Meeting. SCRT: short course radiotherapy with immediate surgery (IS, 3 weeks) or delayed surgery (DS; >3 weeks). CRT: chemoradiation
therapy. *Pathological stage was used for colon, clinical stage was used for rectum. Stage 0-X includes stage 0 or stage X (unknown or not judgeable).
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polypectomies of malignant polyps. The shift towards more local
treatments of CRC can probably be contributed to the start of the
screening program in 2014.
Postoperative outcomes
Overall, postoperative complicated course and mortality
decreased 3.0% and 1.6% in colon cancer, respectively, and 3.8% and
1.3% in rectal cancer, respectively, since 2011e2012. For colon
cancer, multivariable analysis showed a signiﬁcant reduction in the
risk of a complicated postoperative course (AOR 0.74, 95% CI
0.69e0.80), as well as the risk of postoperative mortality (AOR 0.49,
95% CI 0.41e0.59). Similarly, a reduction was found for reinter-
ventions for a surgical complication in 2015e2016 compared to
2011e2012 (Adjusted Odds Ratio (AOR) 0.67, 95% Conﬁdence in-
terval (CI) 0.58e0.77) (Table 3). The risk of non-surgical
complications signiﬁcantly increased between 2011-2012 and
2015e2016 (AOR 1.15, 95% CI 1.07e1.24).
For rectal cancer, multivariable analysis showed a signiﬁcant
decrease for complicated postoperative course (AOR 0.80, 95% CI
0.72e0.88) and mortality (AOR 0.41, 95% CI 0.29e0.57) when
comparing 2015e2016 with 2011e2012 (Table 3). A signiﬁcant in-
crease was found for non-surgical (AOR 1.18, 95% CI 1.06e1.30) and
surgical (AOR 1.15, 95% CI 1.04e1.27) complications, without a
signiﬁcant difference in reinterventions for surgical complications
(AOR 0.90, 95% CI 0.67e1.21).
Risk stratiﬁed comparison of outcomes
Fig. 1 shows the ARR and RRR for each of the predeﬁned 10
subgroups when comparing postoperative outcomes after colon
cancer resection in the period 2015e2016 with 2011e2012
Table 2
Overview from the Netherlands Cancer Registry (NCR) database of the patients diagnosed with primary colorectal cancer between 2009 and 2015 with their corresponding
treatment strategies.
Treatment Year of diagnosis
2009 2010 2011 2012 2013 2014 2015
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Resection - elective 9226 (73) 9368 (72) 9770 (72) 9733 (72) 9391 (71) 10,854 (71) 10,963 (69)
Resection - non-elective 603 (4.8) 588 (4.5) 614 (4.6) 601 (4.4) 605 (4.6) 679 (4.4) 916 (5.7)
Local excision 120 (1) 128 (1) 129 (1) 152 (1.1) 151 (1.1) 240 (1.6) 237 (1.5)
Polypectomy 311 (2.5) 412 (3.2) 385 (2.9) 413 (3) 398 (3) 834 (5.4) 978 (6.1)
(chemo)radiotherapy - no resection 210 (1.7) 262 (2) 315 (2.3) 333 (2.5) 343 (2.6) 375 (2.4) 436 (2.7)
Systemic therapy 873 (6.9) 875 (6.7) 884 (6.6) 889 (6.6) 933 (7) 997 (6.5) 913 (5.7)
radiotherapy and systemic therapy 85 (0.7) 96 (0.7) 124 (0.9) 130 (1) 152 (1.2) 169 (1.1) 160 (1)
Only metastasectomy and/or radiotherapy for metastasis 23 (0.2) 17 (0.1) 19 (0.1) 22 (0.2) 20 (0.2) 24 (0.2) 25 (0.2)
No treatment 1153 (9.1) 1234 (9.5) 1219 (9) 1278 (9.4) 1239 (9.3) 1157 (7.5) 1306 (8.2)
Resection for other indication (incidental ﬁnding) 4 (0) 10 (0.1) 10 (0.1) 11 (0.1) 24 (0.2) 30 (0.2) 15 (0.1)
Treatment unknown 13 (0.1) 11 (0.1) 11 (0.1) 10 (0.1) 5 (0) 5 (0) 6 (0)
Total 12,621 13,001 13,480 13,572 13,261 15,364 15,955
2016 was not yet available.
Table 3
Uni- and multivariable analysis for the odds on different post-operative outcomes for the 2015e2016 compared to 2011e2012.
Outcomes Year of operation ARR (95% CI) Year of operation
2011e2012 2015e2016 2011e2012 2015e2016
Patients N (%) Patients N (%) Odds ratio (CI)
Colonˆ‡* Complicated course 1753/10,357 (16.9) 1478/10,609 (13.9) 3.0% (2.02e3.98) Univariable Ref 0.79 (0.74e0.86)
Multivariable Ref 0.74 (0.69e0.80)
Mortality 347/10,357 (3.4%) 193/10,609 (1.8%) 1.6% (1.17e2.04) Univariable Ref 0.54 (0.45e0.64)
Multivariable Ref 0.49 (0.41e0.59)
Surgical complications 1656/10,357 (16.0) 1838/10,609 (17.3) ¡1.3% (¡0.29 to ¡ 2.31) Univariable Ref 1.10 (1.02e1.18)
Multivariable Ref 1.05 (0.98e1.13)
Reintervention for Surgical complication 1018/1651 (61.5) 944/1838 (51.4) 10.1% (6.81e13.36) Univariable Ref 0.66 (0.57e0.75)
Multivariable Ref 0.67 (0.58e0.77)
Non-surgical complications 1714/10,357 (16.5) 2011/10,609 (19.0) ¡2.5% (¡1.47 to ¡3.53) Univariable Ref 1.18 (1.10e1.27)
Multivariable Ref 1.15 (1.07e1.24)
Rectumˆ#* Complicated course 1205/5256 (22.9) 1001/5253 (19.1) 3.8% (2.24e5.35) Univariable Ref 0.79 (0.72e0.87)
Multivariable Ref 0.80 (0.72e0.88)
Mortality 120/5256 (2.3) 54/5253 (1.0) 1.3% (0.82e1.80) Univariable Ref 0.45 (0.32e0.61)
Multivariable Ref 0.41 (0.29e0.57)
Surgical complications 1129/5256 (21.5) 1233/5253 (23.5) 2.0% (0.40e3.60) Univariable Ref 1.12 (1.02e1.23)
Multivariable Ref 1.15 (1.04e1.27)
Reintervention for Surgical complication 672/1129 (59.5) 627/1233 (50.9) 8.6% (4.59e12.57) Univariable Ref 0.70 (0.60e0.83)
Multivariable Ref 0.90 (0.67e1.21)
Non-surgical complications 1056/5256 (20.1) 1176/5253 (22.4) ¡2.3% (¡0.74 to ¡3.86) Univariable Ref 1.15 (1.05e1.26)
Multivariable Ref 1.18 (1.06e1.30)
The ARR (Absolute Risk Reduction) and RRR (Relative Risk Reduction) of the outcomes of colon cancer for the years 2015e2016 compared to 2011e2012.^The following factors
were included in the multivariable model to correct for differences in case mix between patients; sex, age, ASA, Charlson comorbidity score, BMI, previous abdominal surgery,
tumour related complications, pT-classiﬁcation. zAdded for the colon: location of tumour. #Added for the rectum: received radiotherapy (non, short course or chemo-
radiation), procedure (LAR, APR or different), cT-classiﬁcation, tumour distance from anal verge. *Missing colon (N ¼ 68(0.3%)) or rectal (N ¼ 437 (4.2%)) cancer patients in
corresponding multivariable logistic regression (missing rectal cancer patients primarily consisting of missing tumour distance to anal verge: n ¼ 407). Bold ¼ signiﬁcant
difference.
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(2012e2013 for readmission due to availability in the dataset).
Fig. 2 is showing the same for rectal cancer.
In colon cancer, the risk on a complicated postoperative
course was lower in nine subgroups, with the largest ARR of 6.4%
(RRR 22.3%) in high risk elderly patients (group 8; T1-3N0-2M0,
81 yrs, ASA IIIeIV). The ARR on postoperative mortality was
lower for all subgroups, with again the largest ARR of 5.9% (RRR
52.8%) in the high-risk elderly patients (group 8). Surgical as well
as non-surgical complications showed a slight increase in most
subgroups, but mostly not statistically signiﬁcant. The risk of
undergoing a reintervention for a surgical complication
decreased in all subgroups, with a signiﬁcant ARR of 15.8% in the
high-risk elderly patients (group 8). Readmissions did not
markedly change.
For rectal cancer, a reduced risk of complicated postoperative
course was observed in nine subgroups, with the largest ARR
of 20.0% (RRR 53.8%) in group 5 (T1-3N0-2M0, 60 yrs, ASA III-
eIV). The ARR on mortality was lower for all subgroups, with pa-
tients of group 7 (T1-3N0-2M0, 71e80 yrs, ASA IIIeIV) having the
highest ARR of 6.0% (RRR 71.8%). As in colon cancer, similar changes
over time were observed for the other outcome parameters, with
reduction in reintervention for all subgroups and a highest ARR of
28.6% for group 7 (T1-3N0-2M0, 71e80 yrs, ASA IIIeIV).
Overall, median postoperative LOS decreased from 7 to 5 days
for colon (p < 0.001) and from 8 to 6 days for rectal cancer
(p < 0.001). Fig. 3 shows that the median decrease in LOS, with its
corresponding distribution, was signiﬁcant in 9 out of 10 subgroups
in both colon and rectal cancer patients. The largest decrease in the
Fig. 1. The ARR (Absolute Risk Reduction) and RRR (Relative Risk Reduction) of different outcomes of colon cancer treatment for the years 2015e2016 compared to 2011e2012, risk-
stratiﬁed for different subgroups (1e10). BR ¼ Baseline Risk in 2011e2012 for the outcome of interest. The numbers in the ﬁgure are the ARR for the corresponding subgroup and
outcome. For readmissions, BR of the years 2012e2013 is used because this was not measured prior to 2012. *signiﬁcant difference (p < 0.05) for 2015e2016 compared to
2011e2012 (and 2012e2013 for readmission).
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75th interquartile range (IQR) in both colon and rectal cancer was
found for group 7 (T1-3N0-2M0, 71e80 yrs, ASA IIIeIV). Their 75th
IQR percentage dropped from 14 to 10 days and from 19 to 12 days,
respectively.
Trends in surgical procedures for rectal cancer
Comparing 2011 with 2016, the proportion of patients receiving
a diverting stoma after a (L)ARwith primary anastomosis decreased
from 51.3% to 40% (Fig. 4A). Also, (L)AR with end-colostomy
(Hartmann's procedure) decreased from 26.3% to 19.4%. In
contrast, the proportion of (L) AR with primary anastomosis
without diverting stoma increased from 22% to 40.4%. Reinterven-
tion for anastomotic leakage was 5.6% in 2011 and 6.0% in 2016.
In low rectal cancer (5 cm from the anal verge), patients
increasingly received a non-diverted primary anastomosis (5.4% in
2011 and 14.4% in 2016; Fig. 4B). The proportion of reintervention
for anastomotic leakage in low rectal cancer did not change: 2.3% in
2011 and 2.4% in 2016. The proportions of both APR and LAR with
end-colostomy (Hartmann's procedure) decreased over the years
2011e2016, from 66.3% to 50.8% and 14.2%e10.3%, respectively.
Discussion
This study provides insights in eight years of auditing of CRC
surgery in the Netherlands. The risk proﬁle of patients undergoing
surgery for primary CRC remained largely unchanged, with even a
slight increase in ASA, Charlson comorbidity score and BMI. In
addition, NCR data did not suggest that patients were not regis-
tered in the DCRA or not operated upon because of high risk (risk
aversion). Only small changes in surgical treatment were
observed, mainly related to introduction of screening in 2014.
Fig. 2. The ARR (Absolute Risk Reduction) and RRR (Relative Risk Reduction) of different outcomes of rectal cancer treatment for the years 2015e2016 compared to 2011e2012, risk-
stratiﬁed for different subgroups (1e10). BR ¼ Baseline Risk in 2011e2012 for the outcome of interest. The numbers in the ﬁgure are the ARR for the corresponding subgroup and
outcome. For readmissions, BR of the years 2012e2013 is used because this was not measured prior to 2012. *signiﬁcant difference (p < 0.05) for 2015e2016 compared to
2011e2012 (and 2012e2013 for readmission).
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Overall improvements in mortality and complicated post-
operative course were seen. Remarkably, both surgical and non-
surgical complication rates did not reduce and even revealed a
slight increase for several subgroups of patients. However, surgi-
cal complications seemed to become less severe in both colon and
rectal cancer surgery, as illustrated by the reduced reintervention
rates. The high-risk elderly patients appeared to have beneﬁtted
the most from improvements made in CRC treatment. Regarding
surgical procedures for rectal cancer, a reduction in construction
of temporary diverting stomas and end-colostomies was
observed, even for the group of patients with low rectal cancer.
The unchanged risk proﬁles of patients and the striving for more
bowel continuity in rectal cancer by surgeons did not suggest any
risk aversion.
Postoperative mortality is one of the most important quality
indicators in CRC surgery. Overall, postoperative mortality
decreased from 3.4% to 1.8% in colon cancer and from 2.3% to 1% in
rectal cancer since 2011. The largest absolute risk reduction in
mortality was achieved in the patients at highest operative risk;
from 11.2% to 5.3% (ARR 5.9%) in colon cancer patients of 81 years
and ASA IIIeIV, and from 8.4% to 2.4% (ARR 6.0%) in rectal cancer
patients of 71e80 years and ASA IIIeIV. However, smaller im-
provements in other patient categories might have a signiﬁcant
impact if it concerns a substantial population in absolute numbers.
Fig. 3. Length of stay (LOS) until discharge or in hospital death. LOS is shown as the median in days with its corresponding interquartile range (25th and 75th quartile around
median). Median LOS in 2011e2012 and 2015e2016 are shown for each risk-stratiﬁed subgroup (1e10) and for colon and rectum separately. *signiﬁcant difference (p < 0.05)
between 2015e2016 vs 2011e2012, tested with a non-parametric Mann Whitney U test.
Fig. 4. Stoma construction for (low) anterior resections and low rectal tumours for the years 2011e2016. A. Differences in the construction of a stoma and surgical reintervention for
an anastomotic leakage after a (Low) Anterior Resection for the years 2011e2016. B. Development in treatment modalities and surgical reintervention for an anastomotic leakage for
low rectal tumours (tumours 5 cm from the anal verge) for the years 2011e2016.
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In line with the ﬁndings of Henneman et al., who already
showed that non-surgical complications were a target for
improvement based on DCRA data between 2011 and 2012 [1], we
found a further increase in complication rate. Better registration or
better recognition of complications [18] could have contributed to
this observation. Furthermore, baseline characteristics revealed a
slight increase in comorbidity and BMI, which might increase the a
priori risk of postoperative complications. Nevertheless, one would
have expected any impact of increased awareness and several
improvement measures in perioperative care (i.e. prehabilitation,
Enhanced Recovery After Surgery (ERAS), geriatric consultation) on
this outcome parameter. Therefore, non-surgical complications
should remain an area of attention for the coming years. However,
complications seem to become less severe and probably better
managed considering the observed decreases in reinterventions for
a surgical complication, LOS and postoperative mortality. This also
explains the observed improvements for the composite endpoint of
complicated postoperative course. This beneﬁts both the patients
as well as the healthcare system, as severe complications are large
cost drivers, aside from the initial treatment [19].
Platell et al. showed that patients with benign and malignant
diseases undergoing a low anterior resection with an anastomosis
within 5 cm from the anal verge are the highest risk group for an
anastomotic leak, with ultra-low anterior anastomoses having the
highest (8%) risk of a leak [20]. The systematic review of Huser et al.
showed that constructing a diverting stoma in patients undergoing
a low anterior resection reduces the rate of clinically relevant
anastomotic leakage [21]. However, like Snijder et al. also previ-
ously demonstrated, despite the decreasing construction of a
(diverting) stoma, we found no difference in the rate of reinter-
vention for anastomotic leakage over time, [22]. Furthermore, this
ﬁnding contrasts with the suggested existence of a risk averse
strategy by surgeons promoted through nationwide auditing. In
fact, auditing might have been one of the driving forces behind
further specialization of surgeons, thereby improving the capability
of managing high risk patients. Decreasing rates of APR and Hart-
mann's procedure in distal rectal cancer are likely an effect of this
specialization. This is also illustrated by the increase in the use of
laparoscopic surgery for both colon and rectal cancer resection. In a
previous study, we hypothesized that lower mortality rates after
minimally invasive surgery compared to open surgery might not
purely be related to the surgical technique, but also reﬂects
expertise of surgeons and the hospital setting in which the pro-
cedure is performed [23].
In our study, we found a decreased LOS for colon as well as for
rectal cancer, without an increase in readmission. In agreement
with Pucciarelli et al. [24] and other studies [25], patients with
colon cancer were at lower risks of a prolonged LOS and 30-day
readmission compared to with rectal cancer. Damle et al. looked
at the 30-days readmissions of colorectal resections for multiple
indications and found half of the readmissions occurring within 7
days, with readmitted patients costing double compared to those
not being readmitted [26]. Furthermore, Greenblatt et al. found an
association between readmissions and 1-year mortality after
colectomy for cancer (OR 2.44, 95% CI 2.25e2.65). The lower LOS
and readmission rates again beneﬁts both the patients as well as
the healthcare system.
One can imagine that the success of an audit depends largely on
the quality and intelligibility of the feedback data, as well as on the
users' appreciation of the received data and own efforts in putting it
into practise in the form of improvement cycles [27,28]. When
interpreting the results, it is important to realize that the outcome
measures are only externally reported on a hospital level and not,
as might be the case in other audits, on surgeon level. Besides, as in
many examples of observational research, causality is a major issue.
Without a control group, the possible impact of auditing cannot be
proved. It cannot be excluded that time itself is a confounder and
that improvements would have occurred without auditing and re-
reporting. The relative contribution to the improvements of
evolving insights and techniques, such as the impact of surgical
centralization and specialization [29] and the increasing use of new
techniques such as laparoscopic surgery [23,30], is almost impos-
sible to quantify when looking at overall trends in time. However,
the consistency of demonstrated trends suggests that auditing
matters and leads to new insights. Furthermore, substantial im-
provements in process indicators within a relatively short time
period, such as preoperative MDT discussion, MRI imaging in rectal
cancer and reporting of CRM, can without a doubt be attributed to
auditing [12]. Besides, auditing facilitates international comparison
on treatment patterns and outcomes, enabling valuable discussions
about inter-hospital variability and identifying best practise [31].
An example of this was the observed overtreatment by preopera-
tive radiotherapy in the Netherlands compared to other countries,
with substantial inter-hospital variability [32], leading to guideline
revision, with subsequent rapid implementation as monitored by
the DCRA [33].
The strength of this study is the large numbers of patients and
external validity related to the population-based data reﬂecting
daily practise. But there are also some limitations. A certain de-
gree of missing data is inevitable in population-based studies.
Considering risk adjustment, there is always a possibility that not
all contributing factors were included. For the purpose of this
study, we decided to exclude patients referred through the na-
tional colorectal cancer screening program. This may have led to
an underestimation of the demonstrated improvements. Also, a
better registration over the years and training of surgeons/data-
managers could have had a certain inﬂuence on the reported data.
Finally, the DCRA does not provide information beyond 30 days or
admission.
Conclusion
An overall improvement of outcomes has been demonstrated
during the period of auditing, without signs of risk averse
behaviour (e.g. patient selection). Although the severity of com-
plications is decreasing, areas of future attention remain the
surgical and non-surgical complications. In colon cancer, espe-
cially the high-risk elderly patients have beneﬁtted most of the
improvements made in the past 8 years. For rectal cancer, an
increasing trend is seen in the proportion of (L)AR with primary
anastomosis without diverting stoma and decreasing rates of APR
and low Hartmann's procedure in distal rectal cancer, possibly
reﬂecting specialization.
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